Association between the PINX1 and NAT2 polymorphisms and serum lipid levels

Qing-Hui Zhang1, Rui-Xing Yin1, Feng Huang1, De-Zhai Yang2, Wei-Xiong Lin2 and Shang-Ling Pan3

1Department of Cardiology, Institute of Cardiovascular Diseases, The First Affiliated Hospital, Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China
2Department of Molecular Genetics, Medical Scientific Research Center, Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China
3Department of Pathophysiology, School of Premedical Sciences, Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China

Correspondence to: Rui-Xing Yin, email: yinruixing@163.com

Keywords: the PIN2/TERF1-interacting telomerase inhibitor 1; the N-acetyltransferase 2; single nucleotide polymorphism; lipids; environmental factor

Received: September 27, 2017 Accepted: November 29, 2017 Published: December 09, 2017

Copyright: Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Jing nationality is a relatively conservative and isolated minority in China. Little is known about the association of the PIN2/TERF1-interacting telomerase inhibitor 1 (PINX1) and N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms (SNPs) and serum lipid levels in the Chinese populations. This study aimed to clarify the association of 6 SNPs of the PINX1 and NAT2 and serum lipid levels in two Chinese populations. Genotyping of the SNPs was performed in 1236 Han subjects and 1248 Jing participants. Allelic and genotypic frequencies of these variants (except NAT2 rs1799931) were different between the two ethnic groups. The minor allele carriers had higher triglyceride (TG, rs11776767, rs1495743 and rs1799930), low-density lipoprotein cholesterol (rs6601530) levels and the apolipoprotein (Apo)A1/ApoB ratio (rs1495743) in Han nationality; and higher total cholesterol (rs1961456), TG (rs11776767, rs6601530 and rs1495743) and lower ApoA1 (rs6601530 and rs1799931) levels in Jing minority than the minor allele non-carriers. The SNPs were not statistically independent by the multiple-locus linkage disequilibrium analyses. The integrative haplotypes and gene-by-gene (G × G) interactions on serum lipid traits were also observed in the two populations. Association analysis based on haplotypes and G × G interactions might be powerful than single-locus tests. Differences in serum lipid profiles between the two populations might partially be attributed to these SNPs, their haplotypes and G × G interactions.

INTRODUCTION

Epidemiological studies show that cardiovascular disease (CVD) remains the major cause of death globally [1]. Concerted effort is being taken to reduce this disease burden, especially in developed nations [2, 3]. As an important CVD risk factor and target for therapeutic intervention [4], dyslipidemia is considered as a complex disease caused by multiple environmental factors, including age, gender, smoking, drinking and diabetes, and genetic factors [5–7]. Thus, the discovery of the mutations regulating the serum lipid profiles is very vital in the development of new markers for risk evaluation, diagnosis, and prognosis prediction of CVD.

Recently, genome-wide association studies (GWASes) have found compelling genes for modifying lipid metabolism, including the PIN2/TERF1 interacting, telomerase inhibitor 1 (PINX1, Gene ID: 54984, OMIM: 606505, formerly known as LPTL and LPTS) and the N-acetyltransferase 2 (NAT2, Gene ID: 10, OMIM: 612182,
RESULTS

Subject characteristics

The levels of weight, waist circumference, body mass index (BMI), total cholesterol (TC) and triglyceride (TG) were higher, whereas the values of Apolipoprotein (Apo) A1, the ApoA1/ApoB ratio, diastolic blood pressure and the percentage of individuals who drank alcohol were lower in Jing than in Han populations (P < 0.05–0.001; Table 1). No significant difference was observed between the two ethnic groups in serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and ApoB levels (P > 0.05 for all).

Genotyping

The polymerase chain reaction (PCR) products of PINX1 rs11776767, PINX1 rs6601530, NAT2 rs1961456, NAT2 rs1495743, NAT2 rs1799930 and NAT2 rs1799931 SNPs were 396-, 351-, 164-, 537-, 328- and 429-bp nucleotide sequences after electrophoresis; respectively (Supplementary Figure 1). Using restriction fragment length polymorphism (RFLP) reaction and then analyzed by agarose gel electrophoresis, according to the presence or absence of the enzyme restriction sites, the genotypes of these SNPs were detected (Supplementary Figure 2).

Sequencing

The nucleotide direct sequencing confirmed the genotypes shown by PCR-RFLP; respectively (Supplementary Figure 3).

Genotype and allele distribution

Significant differences were observed between the two ethnic groups in the genotypic and allelic frequencies of the SNPs (P < 0.05–0.001; Tables 2 and 3). All variations exhibited the Hardy-Weinberg equilibrium (HWE; P > 0.05 for all).

Single SNP and serum lipid profiles

As shown in Figure 1, the minor allele carriers had higher the levels of TG (rs11776767, rs1495743, and rs1799930), LDL-C (rs6601530) and the ratio of ApoA1 to ApoB (rs1495743) in Han nationality; and higher TC (rs1961456), TG (rs11776767, rs6601530 and rs1495743), and lower ApoA1 (rs6601530 and rs1799931) levels in Jing minority than the minor allele non-carriers (P < 0.008 for all).

Haplotypes and serum lipid profiles

The tested SNPs were not statistically independent by the multiple-locus linkage disequilibrium (LD) analyses in each population (Figure 2). The commonest
Table 1: Comparison of demographic, lifestyle characteristics and serum lipid levels between the Han and Jing populations

| Parameter                                      | Han   | Jing   | t (x²) | P    |
|-----------------------------------------------|-------|--------|--------|------|
| Number                                        | 1236  | 1248   | -      | -    |
| Male/female                                   | 603/633 | 614/634 | 0.042  | 0.837|
| Age (years)                                   | 58.52±12.97 | 57.92±13.76 | 1.116  | 0.265|
| Height (cm)                                   | 157.05±7.93  | 157.65±7.84 | -1.877 | 0.061|
| Weight (kg)                                   | 56.16±9.40   | 58.47±10.00 | -5.922 | 3.63E-9|
| Body mass index (kg/m²)                       | 22.73±3.18   | 23.46±3.22  | -5.700 | 1.34E-8|
| Waist circumference (cm)                      | 77.44±8.82   | 80.12±9.32  | -7.357 | 2.54E-13|
| Smoking status [n (%)]                        |       |        |        |      |
| Non-smoker                                    | 1008(81.6)  | 1039(83.3) |        |      |
| ≤ 20 cigarettes/day                           | 59(4.8)     | 53(4.2)   | 1.25   | 0.534|
| > 20 cigarettes/day                           | 169(13.7)   | 156(12.5)  |        |      |
| Alcohol consumption [n (%)]                   |       |        |        |      |
| Non-drinker                                   | 993(80.3)   | 1062(85.1) |        |      |
| ≤ 25 g/day                                    | 59(4.8)     | 99(7.9)   |        |      |
| > 25 g/day                                    | 184(14.9)   | 87(7.0)   | 47.106 | 5.90E-11|
| Systolic blood pressure (mmHg)                | 132.77±19.25 | 131.33±21.60 | 1.749  | 0.080|
| Diastolic blood pressure (mmHg)               | 81.48±10.26 | 80.62±10.72 | 2.050  | 0.040|
| Pulse pressure (mmHg)                         | 51.29±15.57 | 50.71±17.16 | 0.871  | 0.384|
| Glucose (mmol/L)                              | 6.72±1.14   | 6.76±1.78  | -0.703 | 0.482|
| Total cholesterol (mmol/L)                    | 4.96±0.89   | 5.19±0.90  | -6.322 | 3.04E-10|
| Triglyceride (mmol/L)                         | 1.34(0.65)  | 1.40(0.76) | -2.565 | 0.010|
| HDL-C (mmol/L)                                | 1.79±0.52   | 1.82±0.46  | -2.105 | 0.136|
| LDL-C (mmol/L)                                | 2.87±0.44   | 2.82±0.42  | 2.630  | 0.143|
| ApoA1 (g/L)                                   | 1.33±0.20   | 1.30±0.24  | 1.917  | 0.002|
| ApoB (g/L)                                    | 1.04±0.24   | 1.06±0.25  | -2.009 | 0.132|
| ApoA1/ApoB                                    | 1.34±0.37   | 1.29±0.38  | 2.759  | 0.003|

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo, apolipoprotein. 1Mean ± SD determined by t-test. 2Because of not normally distributed, the value of triglyceride was presented as median (interquartile range), the difference between the two ethnic groups was determined by the Wilcoxon-Mann-Whitney test.

haplotypes were PINXI G-G and NAT2 G-G-G-G (> 50% of the individuals; Table 4). Significant differences were observed between the Jing and Han nationalities in the frequencies of the PINXI C-A, PINXI G-G, NAT2 A-C-A-A, NAT2 A-C-A-G and NAT2 G-C-G-G haplotypes (P < 0.05–0.001). As shown in the Figure 3, these haplotypes were associated with serum lipid levels. The correlation algorithm based on haplotypes was more powerful for finding more precise and distinct markers than single-locus tests.
The G × G interaction of G-G-G-G-G-G was the commonest one (> 30% of the individuals; Table 5). Significant differences were observed between Jing and Han populations in the frequencies of the C-A-G-G-G-C, G-A-A-C-A-G, G-A-G-C-G-G, G-A-G-G-G-G, G-G-A-C-A-A and G-G-A-C-A-G (P < 0.05–0.001). The G × G interactions on blood lipid profiles are illustrated in Figure 4. The association test based on G × G interactions outperformed other more common single variant association approaches.

### Integrative SNPs, haplotypes and G × G interactions on serum lipid profiles

The integrative association analysis of the SNPs, haplotypes and G × G interactions among the SNPs showed significant differences between the Jing and Han nationalities; and G × G interactions among the SNPs showed significant associated with serum lipid levels (P < 0.05–0.001). In addition, the correlation analysis based on haplotypes and G × G interactions might be more powerful than single-locus tests.

### DISCUSSION

In this study, the main results are as follows: (i) the genotype and allele distributions of 6 SNPs in the PINX1 and NAT2 and the distributions of the haplotypes and the G × G interactions in the two populations is described in the Table 6. After the confounding factors, including age, sex, waist circumference, BMI, smoking, drinking, blood pressure and blood glucose, were adjusted, generalized linear models indicated that the SNPs, haplotypes and G × G interactions were significantly associated with serum lipid levels (P < 0.05–0.001). In addition, the correlation analysis based on haplotypes and G × G interactions might be more powerful than single-locus tests.
Table 3: Allele frequencies of 6 PINXI and NAT2 SNPs between the Han and Jing populations [n (%)]

| SNP          | Allele | Han(n=1236) | Jing(n=1248) | \( \chi^2 \) | P       |
|--------------|--------|-------------|--------------|--------------|---------|
| PINXI rs17767676 | G/C    | 1911(77.3)/561(22.7) | 1860(74.5)/636(25.5) | 5.273 | 0.022  |
| PINXI rs6601530  | G/A    | 1533(62.0)/939(38.0)  | 1448(58.0)/1048(42.0) | 8.287 | 0.004  |
| NAT2 rs1961456   | G/A    | 1802(72.9)/670(27.1)  | 1740(69.7)/756(30.3)  | 6.156 | 0.013  |
| NAT2 rs1495743   | G/C    | 1429(57.8)/1043(42.2) | 1535(61.5)/961(38.5)  | 7.030 | 0.008  |
| NAT2 rs1799930   | G/A    | 1933(78.2)/539(21.8)  | 1860(75.2)/636(24.8)  | 9.279 | 0.002  |
| NAT2 rs1799931   | G/A    | 2177(88.1)/295(11.1)  | 2229(89.3)/267(10.7)  | 1.893 | 0.169  |

PINXI, PIN2/TERF1-interacting telomerase inhibitor 1; NAT2, N-acetyltransferase 2.

interactions indicated that there was probable interaction of the PINXI and NAT2 SNPs on blood lipid levels; and (iii) it proved that association analysis based on haplotypes and G × G interactions might be more powerful than single-locus tests.

As an important predictor of CVD, dyslipidemia is a complex and multifactorial disease induced by multiple environmental factors, including age, sex, obesity, cigarette smoking, alcohol consumption, hypertension, diet and exercise [30, 31] and lots of genetic factors such as lipid-related gene mutations; and their interactions [5, 32]. In this study, we described that the values of TC and TG were higher, while the values of ApoA1 and the ApoA1/ApoB ratio were lower in Jing than in Han nationalities. These results might be owing to the differences in the lipid-related genes and lifestyle between the two ethnic groups. Of the 56 ethnic groups in China, the Han nationality is the largest one and is extensively distributed all around the country. Among the 55 minorities, Jing is the only coastal fishing minority. They reside in a relatively isolated and conservative environment and have similar eating habits. In such a situation, compared with the other inland ethnic groups, it has very unique cultural characteristics and eating customs. Endogamy is still preserved in Jing and intermarriage with people of Han or other nationalities rarely occurred. Due to its relatively closed system of endogamy and unique customs, we inferred that some inheritance features in Jing possibly showed differences from those in Han. In this study, significant differences were observed between the two populations in the genotype and allele distributions of the PINXI rs17767676, PINXI rs6601530, NAT2 rs1961456, NAT2 rs1495743 and NAT2 rs1799930 SNPs. All of the detected mutations were in the HWE. In addition, the frequencies of the PINXI C-A, PINXI G-G, NAT2 A-C-A-A, NAT2 A-C-A-G and NAT2 G-C-G haplotypes and the C-A-G-G-C, G-A-A-C-A-G, G-A-G-C-G-G, G-A-G-G-G-G, G-G-A-C-A-G, and G-G-A-C-A-G G × G interactions also showed quantitative significantly differences between the two populations. These findings indicated that the distributions of the detected 6 SNPs of PINXI and NAT2, their haplotypes and G × G interactions possibly had a racial/ethnic-specificity and these genetic heterogeneities might be correlated to the differences between the Jing and Han nationalities in serum lipid profiles.

The locations of the PINXI and NAT2 are very close, both of which are on the chromosome 8p. Data have showed that PINXI has functional role in inhibition of telomerase activity and reduction of telomere length [33]. The expression of PINXI significantly decreased some human cancers and was correlated to the adverse outcome of cancer patients. A relevant study [34] showed that the PINXI mutations increased the risk of carotid intima media thickness, which is used to determine atherosclerosis, a chronic formation process caused by excessive cholesterol deposition in the arterial intima [35]. Teslovich et al. [26] reported the effect of PINXI variants on high serum TG concentrations, which was successfully replicated by Willer et al. [36]. However, the exact mechanism by which PINXI affects serum lipid profiles is still unclear. The protein product of the NAT2 is capable of N-acetylation and O-acetylation which are implicated in the metabolism and detoxification of naturally occurring xenobiotics, including carcinogens and drugs [37]. The acetylator phenotype is determined by studying the acetylation of variety drugs such as caffeine, dapsone, sulfadimidine or isoniazid. Therefore, the acetylation capacity in humans has been linked to NAT2 polymorphisms, which alters susceptibility to cancer and other diseases including adverse drug reactions [38, 39]. Al-Shaqha et al. reported that the NAT2 alleles were associated with the type 2 diabetes mellitus [40], which is closely related to the abnormal blood lipid profiles. Studies describing the effect of NAT2 alleles on serum lipid profiles are few [25, 26] and the specific mechanism of the influence of NAT2 on serum lipid profiles is still unclear. Because of the close locations of PINXI and NAT2, they may interact with each other on serum lipid profiles. Therefore, the specific mechanism of PINXI, NAT2 and their interactions on serum lipid profiles still needs to be continued in-depth studied, which probably provide a novel therapeutic target.

The current study indicated that the effect of the PINXI and NAT2 SNPs, their haplotypes and G × G interactions on serum lipid parameters might have a racial/ethnic specificity. Many GWASes and replicated
Figure 1: Association of single SNP and serum lipid levels. TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo, apolipoprotein. *P < 0.008 (corresponding to P < 0.05 after adjusting for 6 independent tests by the Bonferroni correction, this value was considered statistically significant) and †P < 0.001.

Figure 2: Linkage disequilibrium (LD) analyses of the PINX1 and NAT2 SNPs. LD among the (1) PINX1 rs11776767, (2) PINX1 rs6601530, (3) NAT2 rs1961456, (4) NAT2 rs1495743, (5) NAT2 rs1799930, (6) NAT2 rs1799931 SNPs in the Han (A), Jing (B). The LD status is expounded by the $r^2$. 
Figure 3: Association of the haplotypes and serum lipid traits. The haplotype was presented as PINX1 rs11776767-rs6601530 and NAT2 rs1961456-rs1495743-rs1799930-rs1799931. TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo, apolipoprotein. *P < 0.05, †P < 0.01 and ‡P < 0.001.

Table 4: Haplotype frequencies of 6 PINX1 and NAT2 SNPs in the Han and Jing populations [n (frequency)]

| Haplotype       | Han          | Jing         | χ²     | P-value  | Odd Ratio [95% CI] |
|-----------------|--------------|--------------|--------|----------|-------------------|
| PINX1 C-A       | 551.99(0.223)| 635.98(0.255)| 6.775  | 0.009261 | 0.841 [0.738~0.958] |
| PINX1 G-A       | 384.01(0.155)| 408.02(0.163)| 0.612  | 0.434140 | 0.941 [0.808~1.096] |
| PINX1 G-G       | 1535.99(0.621)| 1451.98(0.582)| 8.137  | 0.004350 | 1.180 [1.053~1.322] |
| NAT2 A-C-A-A    | 276.00(0.112)| 227.97(0.091)| 6.504  | 0.010793 | 1.272 [1.057~1.531] |
| NAT2 A-C-A-G    | 288.00(0.117)| 408.03(0.163)| 20.827 | 5.15E-6  | 0.686 [0.583~0.807] |
| NAT2 A-C-G-A    | 59.98(0.024)| 23.99(0.010) | -      | -        | -                 |
| NAT2 A-C-G-G    | 72.00(0.029)| 96.01(0.038) | 2.969  | 0.084900 | 0.761 [0.558~1.039] |
| NAT2 G-C-G-G    | 372.02(0.150)| 288.00(0.115)| 14.870 | 0.000116 | 1.383 [1.172~1.631] |
| NAT2 G-G-G-G    | 1403.97(0.568)| 1451.96(0.582)| 0.141  | 0.707658 | 0.978 [0.873~1.096] |
| NAT2 G-G-G-A    | 0.00(0.000)| 0.03(0.000)  | -      | -        | -                 |

The haplotype is combined with PINX1 rs11776767-rs6601530, NAT2 rs1961456-rs1495743-rs1799930-rs1799931. PINX1, PIN2/TERF1-interacting telomerase inhibitor 1; NAT2, N-acetyltransferase 2.
studies have reported that the SNPs near the PINX1 and NAT2 were associated with serum lipid phenotypes [23-26, 41]. The PINX1 rs11776767 SNP has been associated with TG in many nationalities [23, 26], however, the directions of effect were different among different ethnic groups. The minor allele carriers had a positive correlation with TG in East Asian, South Asian and African American, but an opposite effect in European. Likewise, the NAT2 rs1961456 and NAT2 rs1495743 SNPs have been associated with TC and TG respectively, and had diverse directions of effect on serum lipid profiles in different populations [26]. In this study, we successfully replicated the association of the PINX1 rs11776767 and NAT2 rs1495743 SNPs with TG in both populations; and the NAT2 rs1961456 SNP with TC in the Jing minority. The minor allele carriers of PINX1 rs11776767, NAT2 rs1495743 and rs1961456 SNPs consensually had higher serum lipid parameters than the minor allele non-carriers. What’s more, we also explored the minor allele carriers had higher LDL-C (PINX1 rs6601530), the ratio of ApoA1 to ApoB (NAT2 rs1495743) and TG (NAT2 rs1799930) than the minor allele non-carriers in Han. The minor allele carriers of PINX1 rs6601530 had higher TG and lower ApoA1 than the minor allele non-carriers in Jing minority. Previous studies proved that the strength of a single marker association analysis might suffer for LD information included in flanking markers was neglected. Haplotypes (which can be regarded as a collection of ordered markers) might increase power over individual, unorganised markers [42]. In addition, blood lipid profiles are influenced by multiple genes and their interactions. In this study, multiple-locus LD analyses showed that the tested loci were not statistically independent in both populations. Therefore, the association tests based on the haplotypes and G × G inter-locus interactions have been conducted. We found that the haplotypes and G × G interactions were also associated with serum lipid levels and the association had a same racial specificity. The inconsistent association among different populations might be attributed to genetic heterogeneity.

Figure 4: G × G interactions of the PINX1 and NAT2 SNPs on serum lipid levels. The order was presented as rs11776767-rs6601530-rs1961456-rs1495743-rs1799930-rs1799931. *P < 0.05, **P < 0.01 and ***P < 0.001.
In addition, environmental factors such as lifestyles and dietary habits are also closely correlated to serum lipid profiles [30, 43]. Jing is a coastal ethnic minority, which makes a living out of fishing [44] and fish is one of the most popular dishes they eat. Fishes are rich in long-chain n-3 (ω-3) polyunsaturated fatty acids (LCn-3PUFA), which is beneficial to serum lipid profiles. However, previous studies also showed that LCn-3PUFA could effectively increase TC, TG and LDL-C concentrations and reduce HDL-C concentrations [45, 46]. In this study, we also showed that the values of waist circumference, weight and BMI were higher, whereas the rate of alcohol consumption was lower in Jing than in Han. A study conducted in young black and white adults showed that a 10-year weight gain tended to have disadvantageous effect on the levels of TG, LDL-C and HDL-C [47]. Williams et al. [48] showed that the rise of waist circumference and BMI increased the risk of hypercholesterolemia during the seven-year follow-up. A moderate alcohol consumption was causally related to the low risk of CVD through mainly increasing serum HDL-C and ApoA1 concentrations [49]. However, excessive intake of alcohol has been proved to lead to hypertriglyceridemia [50], which is an important predictor of CVD.

Several potential limitations could not be neglected in this study. First, compared with lots of previous GWASes, the sample size was comparatively less. Next, several confounding factors, including age, sex, BMI, smoking, drinking and blood pressure might have influence on blood lipid profiles among different genotypes in the two populations, although we have adjusted these factors for the statistical analysis. What’s more, the dietary influence on serum lipid profiles could not been eliminated during the statistical analysis. Last but not the least, in this study, we have only detected the association of mutations in the PINX1 and NAT2 SNPs, their haplotypes and G × G interactions were associated with serum lipid parameters in the Jing and Han nationalities, but the association was different between the two populations. The association analysis based on haplotypes and G × G interactions might be powerful than single-

| G × G interaction | Han | Jing | χ² | P-value | Odd Ratio[95%CI] |
|-------------------|-----|------|-----|---------|-----------------|
| A                 | B   | C    | D   | E       | F               |
| C                 | A   | G    | G   | G       | C               | 92.87(0.038) | 131.96(0.053) | 6.531 | 0.010621 | 0.703 [0.535–0.922] |
| C                 | A   | G    | G   | G       | G               | 456.00(0.184) | 504.00(0.202) | 2.173 | 0.140400 | 0.899 [0.780–1.036] |
| C                 | A   | G    | G   | C       | G               | 3.13(0.001)   | 0.03(0.000)   | -    | -       | -                |
| G                 | G   | A    | C   | A       | A               | 12.00(0.005)  | 15.56(0.006)  | -    | -       | -                |
| G                 | A   | A    | C   | A       | G               | 36.00(0.015)  | 108.00(0.043) | 36.029 | 2.00E-009 | 0.328 [0.224–0.480] |
| G                 | A   | A    | C   | G       | A               | 0.00(0.000)   | 23.98(0.010)  | -    | -       | -                |
| G                 | A   | A    | C   | G       | G               | 36.00(0.015)  | 60.01(0.024)  | -    | -       | -                |
| G                 | A   | G    | C   | G       | G               | 183.13(0.074) | 60.05(0.024)  | 67.690 | 2.01E-016 | 3.275 [2.433–4.410] |
| G                 | A   | G    | G   | G       | G               | 96.00(0.039)  | 140.42(0.056) | 8.095  | 0.004453 | 0.681 [0.522–0.889] |
| G                 | A   | A    | C   | A       | A               | 264.00(0.107) | 212.40(0.085) | 7.121  | 0.007635 | 1.295 [1.071–1.567] |
| G                 | G   | A    | C   | A       | G               | 252.00(0.102) | 300.04(0.120) | 3.950  | 0.046902 | 0.835[0.699–0.998] |
| G                 | G   | A    | C   | G       | G               | 36.00(0.015)  | 36.00(0.014)  | -    | -       | -                |
| G                 | G   | G    | C   | G       | G               | 116.87(0.047) | 95.96(0.038)  | 2.497  | 0.114075 | 1.249 [0.947–1.646] |
| G                 | G   | G    | G   | G       | A               | 0.00(0.000)   | 0.04(0.000)   | -    | -       | -                |
| G                 | G   | G    | G   | G       | G               | 828.00(0.335) | 807.52(0.324) | 1.015  | 0.313789 | 1.064 [0.943–1.199] |
| G                 | G   | A    | G   | G       | A               | 24.00(0.010)  | 0.00(0.000)   | -    | -       | -                |
| G                 | A   | A    | C   | A       | G               | 36.00(0.015)  | 0.00(0.000)   | -    | -       | -                |

A, PINX1 rs11776767 G>C; B, PINX1 rs6601530 G>A; C, NAT2 rs1961456 G>A; D, NAT2 rs1495743 G>C; E, NAT2 rs1799930 G>A; F, NAT2 rs1799931 G>A; PINX1, PIN2/TERF1-interacting telomerase inhibitor 1; NAT2, N-acetyltransferase 2.
Table 6: Association of integrative *PINX1* and *NAT2* mutations, haplotypes and G × G interactions with serum lipid traits in the Han and Jing populations

| Lipid | Mutation/ Haplotype/G × G interaction | Affected phenotype/ Other phenotype | Unstandardized Coefficients | Standardized Coefficients | t   | P     |
|-------|--------------------------------------|------------------------------------|-----------------------------|---------------------------|-----|-------|
|       |                                      |                                    | Beta | Std.error | Beta |       |
| Han   | PINX1 rs11776767 G/C                 | -0.255                            | -0.143                       | -4.507                    | 7.20E-6 |     |
|       | NAT2 rs1799931 G/A                   | -0.131                            | -0.064                       | -2.024                    | 0.043 |     |
|       | PINX1 C-A Carriers/Non-carriers      | -0.154                            | -0.086                       | -3.004                    | 0.003 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | 0.199                             | 0.068                        | 2.349                     | 0.019 |     |
|       | PINX1 rs11776767 GG/GC/CC            | 0.108                             | 0.124                        | 4.015                     | 6.31E-5 |     |
|       | NAT2 rs1799931 GG/GA/AA              | 0.125                             | 0.123                        | 3.989                     | 7.04E-5 |     |
|       | NAT2 A-C-A-G Carriers/Non-carriers   | -0.108                            | -0.085                       | -2.946                    | 0.003 |     |
|       | G-A-G-C-G-G Carriers/Non-carriers   | -0.165                            | -0.107                       | -3.717                    | 2.11E-4 |     |
|       | LDL PINX1 rs6601530 GG/GA/AA         | 0.069                             | 0.108                        | 3.819                     | 1.41E-4 |     |
|       | G-G-A-C-A-A Carriers/Non-carriers   | -0.067                            | -0.060                       | -2.085                    | 0.037 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | 0.107                             | 0.072                        | 2.520                     | 0.012 |     |
|       | ApoA1 PINX1 G-G Carriers/Non-carriers| 0.062                             | 0.073                        | 2.736                     | 0.006 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | 0.108                             | 0.095                        | 3.244                     | 0.001 |     |
|       | ApoB G-G-A-C-A-A Carriers/Non-carriers| -0.039                      | -0.068                       | -2.427                    | 0.015 |     |
|       | ApoA1/ ApoB NAT2 rs1495743 GG/GC/CC  | -0.072                            | -0.110                       | -3.879                    | 1.11E-4 |     |
|       | PINX1 C-A Carriers/Non-carriers      | 0.062                             | 0.099                        | 3.402                     | 0.001 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | -0.108                            | -0.095                       | -3.244                    | 0.001 |     |
| Jing  | TC G-G-A-C-A-G Carriers/Non-carriers| 0.154                             | 0.073                        | 2.736                     | 0.006 |     |
|       | NAT2 rs1495743 G/G                  | 0.166                             | 0.088                        | 2.936                     | 0.003 |     |
|       | NAT2 rs1799931 GG/GA/AA             | -0.138                            | -0.066                       | -2.186                    | 0.029 |     |
|       | NAT2 A-C-A-G Carriers/Non-carriers   | 0.171                             | 0.085                        | 3.132                     | 0.002 |     |
|       | NAT2 G-C-G-G Carriers/Non-carriers   | 0.141                             | 0.057                        | 2.132                     | 0.033 |     |
|       | HDL-C NAT2 rs1961456 GG/GA/AA       | -0.085                            | -0.123                       | -3.291                    | 0.001 |     |
|       | rs1495743 G/A                       | 0.081                             | 0.084                        | 2.245                     | 0.025 |     |
|       | NAT2 G-C-G-G Carriers/Non-carriers   | 0.077                             | 0.061                        | 2.242                     | 0.025 |     |
|       | ApoA1 PINX1 rs11776767 GG/GC/CC      | 0.048                             | 0.125                        | 3.831                     | 1.34E-4 |     |
|       | PINX1 rs6601530 GG/GA/AA             | -0.056                            | -0.161                       | -4.961                    | 7.97E-7 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | -0.128                            | -0.164                       | -5.943                    | 3.62E-9 |     |
|       | ApoB PINX1 rs6601530 GG/GA/AA        | -0.034                            | -0.086                       | -2.837                    | 0.005 |     |
|       | NAT2 rs1799931 G/A                  | -0.052                            | -0.075                       | -2.457                    | 0.014 |     |
|       | G-A-G-G-G-G Carriers/Non-carriers   | -0.097                            | -0.110                       | -3.972                    | 0.000 |     |

HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Apo, apolipoprotein; *PINX1*, PIN2/TERF1-interacting telomerase inhibitor 1; *NAT2*, N-acetyltransferase 2.
locus tests. Differences in serum lipid profiles between the two ethnic groups might partially be attributed to the PINX1 and NAT2 SNPs.

MATERIALS AND METHODS

Study populations

The current study included 1236 (603 males, 48.8% and 633 females, 51.2%) unrelated subjects of Han nationality and 1248 unrelated participants (614 males, 49.2% and 634 females, 50.8%) of Jing minority. They were randomly selected from our previous stratified randomized samples. All participants were rural agricultural (Han) and/or fishery (Jing) workers living in Jiangping Town, Dongxing City, Guangxi Zhuang Autonomous Region, People’s Republic of China. The participants’ age ranged from 15–80 years with a mean age of 58.52 ± 12.97 years in Han and 57.92 ± 13.76 years in Jing, respectively. All participants were essentially healthy and had no evidence of diseases related to atherosclerosis, CVD, and diabetes. Any participant had a history of taking medications known to affect serum lipid levels (lipid-lowering drugs such as statins or fibrates, beta blockers, diuretics, or hormones) was excluded before the blood sample was taken. The study design was approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University (No: Lunshen-2011-KY-Guoj-001; Mar. 7, 2011). Informed consent was obtained from all participants.

Epidemiological survey

The epidemiological survey was carried out using internationally standardized method, following a common protocol. Information on demographics, socioeconomic status, and lifestyle factors was collected with standardized questionnaires. Cigarette smoking status was categorized into groups of cigarettes per day: 0, ≤ 20 and > 20 [51]. Alcohol consumption was categorized into groups of grams of alcohol per day: 0, ≤ 25 and > 25 [52]. Several parameters such as blood pressure, height, weight and waist circumference were measured, while BMI (kg/m²) was calculated. Hypertension was defined as a systolic blood pressure of 140 mmHg or greater, and/or a diastolic blood pressure of 90 mmHg or higher, or the use of antihypertensive drugs [53]. A BMI less than 18.5, 18.5 to 24, 24 to 28, and greater than 28 kg/m² was defined as underweight, normal weight, overweight and obesity, respectively [54]. Likewise, waist circumference was categorized into normal (≤ 85 cm for males and ≤ 80 cm for females) and abdominal obesity (> 85 cm for males and > 80 cm for females) subgroups [55].

Biochemical measurements

A fasting venous blood sample of 5 ml was drawn from the participants. The levels of TC, TG, HDL-C and LDL-C in the samples were determined by enzymatic methods with commercially available kits. Serum ApoA1 and ApoB levels were assessed by the immune-turbid metric immunoassay. Fasting blood glucose was determined by glucose meter. The normal values of serum TC, TG, HDL-C, LDL-C, ApoA1 and ApoB levels, and the ratio of ApoA1 to ApoB in our Clinical Science Experiment Center were 3.10-5.17, 0.56-1.70, 1.16-1.42, 2.70-3.10 mmol/L, 1.20-1.60, 0.80-1.05 g/L, and 1.00-2.50; respectively. The individuals with TC > 5.17 mmol/L and/or TG > 1.70 mmol/L were defined as hyperlipidemic [56].

SNP selection

We selected 6 SNPs in the PINX1 and NAT2 with the following assumption: (i) tag SNPs, which were established by Haploview (Broad Institute of MIT and Harvard, Cambridge, MA, USA, version4.2), (ii) functional mutations (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) in functional areas of the gene fragment from NCBI dbSNP Build 123 (http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/SNP/); (iii) a known minor allele frequency (MAF) higher than 1% in European ancestry from the Human Genome Project Database; and (iv) mutations might be associated with the lipid-related traits or cardiometabolic risk in the latest studies.

Genotyping

DNA was isolated from blood samples using DNA Blood Midi kits (Qiagen, Hilden, Germany) following the protocol recommended by the vendor. Six SNPs were genotyped by PCR-RFLP. The characteristics of each SNP and the details of each primer pair, annealing temperature, length of the PCR products and corresponding restriction enzyme used for genotyping are summarized in Supplementary Tables 1 and 2. The PCR products of the samples (two samples of each genotype) were sequenced with an ABI Prism 3100 (Applied Biosystems, International Equipment Trading Ltd., Vernon Hill, IL, USA) in Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., China.

Statistical analyses

The statistical analysis was performed with the statistical software SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Quantitative variables were presented as the mean ± SD for those, that are normally distributed, whereas the medians and interquartile ranges for TG, which is not normally distributed. General characteristics between the two ethnic groups were compared by Student’s unpaired t-test. The frequencies of the genotypes, alleles, haplotypes and $G \times G$ interactions between the two ethnic groups were analyzed by the chi-squared test; and the standard goodness-of-fit verified the test HWE. The Pair-wise
LD, the frequencies of haplotypes and G × G interactions among the SNPs were calculated using Haploview (version 4.2; Broad Institute of MIT and Harvard). The association of the genotypes, haplotypes and G × G interactions with lipid phenotypic variations was tested by the analysis of covariance (ANCOVA). Any SNPs associated with serum lipid profiles at a value of P < 0.008 (corresponding to P < 0.05 after adjusting for 6 independent tests by the Bonferroni correction) were considered statistically significant. Generalized linear models were used to assess the association of the genotypes (common homozygote genotype = 0, heterozygote genotype = 1, rare homozygote genotype = 2), alleles (the minor allele non-carrier = 0, the minor allele carrier = 1), haplotypes (the haplotype non-carrier = 0, the haplotype carrier = 1) and G × G interactions (the G × G interaction non-carrier = 0, the G × G interaction carrier = 1) with serum lipid parameters. The factors of age, gender, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, pulse pressure, cigarette smoking, alcohol consumption and fasting blood glucose levels were adjusted for the statistical analysis. The pattern of pair-wise LD between the selected mutations was measured by D′ and r² using the Haploview software. Two-sided P value of less than 0.05 was considered statistically significant for the remaining parameters.

Author contributions
Q.-H.Z. conceived the study, participated in the design, undertook genotyping, performed the statistical analyses, and drafted the manuscript. R.-X.Y. conceived the study, participated in the design, carried out the epidemiological survey, collected the samples, and helped to draft the manuscript. F.H., D.-Z.Y., W.-X.L. and S.-L.P. carried out the epidemiological survey, collected the samples, and helped to draft the manuscript. R.-X.Y., et al. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-negative human cancer cells. Cancer Res. 2009; 69:75-83.

Acknowledgments and funding
The authors acknowledge the essential role of the funding of the National Natural Science Foundation of China (No: 81160111) and the Innovation Project of Guangxi Graduate Education in this motif.

Conflicts of interest
The authors have no potential conflicts of interest to report.

References
1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016; 253:281-344.
2. Unal B, Critchley JA, Caperwell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004; 109:1101-1107.
3. Peeters A, Nusselder WJ, Stevenson C, Boyko EJ, Moon L, Tonkin A. Age-specific trends in cardiovascular mortality rates in the Netherlands between 1980 and 2009. Eur J Epidemiol. 2011; 26:369-373.
4. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular C, Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006; 22:913-927.
5. Ordovas JM, Shen AH. Genetics, the environment, and lipid abnormalities. Curr Cardiol Rep. 2002; 4:508-513.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2899-2934.
7. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384:626-635.
8. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res. 2000; 6:1372-1377.
9. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35:46-54.
10. Kishimoto Y, Shiotani G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H. Frequent loss of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35:46-54.
11. Kishimoto Y, Shiotani G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H. Frequent loss of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35:46-54.
12. Cheung DH, Ho ST, Lau KH, Lin J, Sun SP, Yang P, Wang XX, Huang PT, Huung CF, Peng Y, et al. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res. 2009; 69:75-83.
13. Cheung DH, Ho ST, Lau KH, Lin J, Sun SP, Yang P, Wang XX, Huang PT, Huung CF, Peng Y, et al. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res. 2009; 69:75-83.
attenuates the PinX1 inhibition on telomerase activity. Sci Rep. 2017; 7:43650.

13. Li JP, Zhu SW, Chen YH, Wang XL, Gao X. Suppression of PinX1 resulted in telomere dysfunction and enhanced radiosensitivity in osteosarcoma cell lines. Neoplasma. 2015; 62:887-893.

14. Noreira-Reyes MY, Rivas-Torres MA, Onate-Ocana LF, Valles AJ, Baranda-Avila N, Langley E. Novel role for PINX1 as a coregulator of nuclear hormone receptors. Mol Cell Endocrinol. 2015; 414:9-18.

15. Stanley LA, Sim E. Update on the pharmacogenetics of NATs: structural considerations. Pharmacogenomics. 2008; 9:1673-1693.

16. Sim E, Fakis G, Laurieri N, Boukouvala S. Arylamine N-acetyltransferases—from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention. Adv Pharmacol. 2012; 63:169-205.

17. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, Kawamata A. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology. 2008; 254:170-183.

18. McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014; 24:409-425.

19. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Gueguenou M, Louis N, Ly K, Schurr J, Tishkoff SA, Duran B, et al. The genomic tree of human populations. Science. 2009; 324:710-713.

20. Ruiz JD, Martinez C, Anderson K, Gross M, Lang NP, Garcia-Martín E, Agundez JA. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS One. 2012; 7:e44629.

21. Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol. 2013; 87:2129-2139.

22. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 1995; 55:3531-3536.

23. Jeemon P, Pettigrew K, Sainsbury C, Prabhakaran D, Padmanabhan S. Implications of discoveries from genome-wide association studies in current cardiovascular practice. World J Cardiol. 2011; 3:230-247.

24. Johansen CT, Wang J, Lanktree MB, McIntyre AD, Ban MR, Martins RA, Kennedy BA, Hassell RG, Visser ME, Schwartz SM, Voight BF, Elousoa R, Salomaa V, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011; 31:1916-1926.

25. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011; 52:189-206.

26. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466:707-713.

27. Lin JH, Liu ZH, Lv FJ, Fu YG, Fan XL, Li SY, Lu JM, Liu XY, Xu AL. Molecular analyses of HLA-DRB1, -DPB1, and -DQB1 in Jinan ethnic minority of Southwest China. Hum Immunol. 2003; 64:830-834.

28. Guo T, Yin RX, Huang F, Yao LM, Yin WX, Pan SL. Association between the DOCK7, PCSK9 and GALNT2 gene polymorphisms and serum lipid levels. Sci Rep. 2016; 6:19079.

29. Sun JQ, Yin RX, Shi GY, Shen SW, Chen X, Bin Y, Huang F, Wang W, Lin WX, Pan SL. Association of the ARL15 rs6450176 SNP and serum lipid levels in the Jinan and Han populations. Int J Clin Exp Pathol. 2015; 8:12977-12994.

30. Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. J Atheroscler Thromb. 2000; 7:177-197.

31. Barnard RJ. Effects of lifestyle modification on serum lipids. Arch Intern Med. 1991; 151:1389-1394.

32. Ordovas JM, Robertson R, Cleirigh EN. Gene-gene and gene-environment interactions defining lipid-related traits. Curr Opin Lipidol. 2011; 22:129-136.

33. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 2001; 107:347-359.

34. Li C, Chen W, Jiang F, Simino J, Srinivasan SR, Berenson GS, Mei H. Genetic association and gene-smoking interaction study of carotid intima-media thickness at five GWAS-indicated genes: the Bogalusa Heart Study. Gene. 2015; 562:226-231.

35. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013; 424:245-252.

36. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Gamma A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, et al. Discovery and refinement of loci associated with lipid levels. Nature Genet. 2013; 45:1277-1283.

37. Lee MS, Su L, Christiani DC. Synergistic effects of NAT2 slow and GSTM1 null genotypes on carcinogen DNA damage in the lung. Cancer Epidemiol Biomarkers Prev. 2010; 19:1492-1497.
39. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012; 13:31-41.

40. Al-Shaqha WM, Alkharfy KM, Al-Daghri NM, Mohammed AK. N-acetyltransferase 1 and 2 polymorphisms and risk of diabetes mellitus type 2 in a Saudi population. Ann Saudi Med. 2015; 35:214-221.

41. Goldberg JJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011; 31:1716-1725.

42. Akey J, Jin L, Xiong M. Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet. 2001; 9:291-300.

43. Erkkila AT, Sarkkinen ES, Lehto S, Pyorala K, Uusitupa MI. Dietary associates of serum total, LDL, and HDL cholesterol and triglycerides in patients with coronary heart disease. Prev Med. 1999; 28:558-565.

44. Kieu NT, Yasugi E, Lien do TK, Anh NT, Do TT, Khoi HH, Kido T, Kondo K, Itakura H, Chuyen NV, Yamamoto S, Oshima M. Serum fatty acids, lipoprotein(a) and apolipoprotein composition of rural, suburban and urban populations in North Vietnam. Asia Pac J Clin Nutr. 2000; 9:66-62.

45. Sala-Vila A, Guasch-Ferré M, Hu FB, Sánchez-Tainta A, Bulló M, Serra-Mir M, López-Sabater C, Sorlí JV, Arós F, Fiol A, Muñoz MA, Serra-Majem L, Martinez JA, et al. Dietary alpha-linolenic acid, marine omega-3 fatty acids, and mortality in a population with high fish consumption: findings from the PREVencion con Dileta MEDiterranea (PREDIMED) Study. J Am Heart Assoc. 2016; 5:e002543.

46. Dias CB, Wood LG, Garg ML. Effects of dietary saturated and n-6 polyunsaturated fatty acids on the incorporation of long-chain n-3 polyunsaturated fatty acids into blood lipids. Eur J Clin Nutr. 2016; 70:812-818.

47. Norman JE, Bild D, Lewis CE, Liu K, West DS. The impact of weight change on cardiovascular disease risk factors in young black and white adults: the CARDIA study. Int J Obes Relat Metab Disord. 2003; 27:369-376.

48. Williams PT. Changes in body weight and waist circumference affect incident hypercholesterolemia during 7 years of follow-up. Obesity. 2008; 16:2163-2168.

49. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999; 319:1523-1528.

50. Van de Wiel A. The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med. 2012; 2012:862504.

51. Okuyemi KS, Ahluwalia JS, Richter KP, Mayo MS, Resnicow K. Differences among African American light, moderate, and heavy smokers. Nicotine Tob Res. 2001; 3:45-50.

52. Kerr WC, Mulia N, Zemore SE. U.S. trends in light, moderate, and heavy drinking episodes from 2000 to 2010. Alcohol Clin Exp Res. 2014; 38:2496-2501.

53. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Jf hypertens. 2003; 21:1983-1992.

54. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 2000; 894:i-xii, 1-253.

55. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ. 1995; 311:1401-1405.

56. Durrington P. Dyslipidaemia. Lancet. 2003; 362:717-731.